Phio Pharmaceuticals Corp. announced on January 2, 2025, the publication of research titled 'Self-delivering RNAi Compounds for Reduction of Hyperpigmentation' in the December 2024 issue of Clinical, Cosmetic and Investigational Dermatology. The article presents proof-of-concept data for RXI-231, an INTASYL compound designed to target and reduce tyrosinase (TYR) gene expression.
RXI-231 significantly reduced tyrosinase mRNA expression and, correspondingly, melanin content in both normal human melanocytes and the 3D human epidermal culture, MelanoDerm model. Application of INTASYL RXI-231 every other day visibly reduced pigmentation in the 3D epidermal cultures. Furthermore, evaluation using the MatTek EpiDerm Skin Irritation model confirmed its non-irritant profile.
Robert Bitterman, CEO of Phio Pharmaceuticals, stated that the publication underscores the innovative and expansive potential of INTASYL compounds in dermatological conditions. While further characterization and clinical testing are needed, RXI-231 shows promise in treating hyperpigmentation disorders, demonstrating the versatility of the INTASYL platform beyond immuno-oncology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.